UBS Asset Management Americas Inc. lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 427,127 shares of the medical research company’s stock after selling 9,706 shares during the period. UBS Asset Management Americas Inc. owned about 1.44% of Bio-Rad Laboratories worth $96,663,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Canada Pension Plan Investment Board acquired a new stake in Bio-Rad Laboratories in the 2nd quarter valued at about $113,000. Pacad Investment Ltd. acquired a new stake in Bio-Rad Laboratories in the 2nd quarter valued at about $113,000. Turner Investments LLC acquired a new stake in Bio-Rad Laboratories in the 2nd quarter valued at about $136,000. Capital Analysts LLC acquired a new stake in Bio-Rad Laboratories in the 2nd quarter valued at about $170,000. Finally, Meadow Creek Investment Management LLC raised its position in Bio-Rad Laboratories by 17.6% in the 1st quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock valued at $175,000 after purchasing an additional 132 shares in the last quarter. 62.84% of the stock is currently owned by institutional investors.
In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total transaction of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 28.29% of the company’s stock.
BIO has been the topic of a number of analyst reports. BidaskClub lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and reduced their price target for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. Zacks Investment Research lowered Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $240.80.
Shares of Bio-Rad Laboratories, Inc. (BIO) opened at 230.89 on Friday. The firm has a market cap of $6.84 billion, a price-to-earnings ratio of 456.30 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52-week low of $154.89 and a 52-week high of $242.79. The firm has a 50-day moving average price of $220.74 and a 200-day moving average price of $217.89.
WARNING: This report was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2017/09/22/ubs-asset-management-americas-inc-has-96-66-million-holdings-in-bio-rad-laboratories-inc-bio.html.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.